Active Ingredient History

  • Now
Baricitinib (trade name Olumiant) is an investigational drug for rheumatoid arthritis (RA), being developed by Incyte and Eli Lilly. Baricitinib is a selective JAK1 and JAK2 inhibitor with IC50 of 5.9 nM and 5.7 nM in cell-free assays. In February 2017 Baricitinib was approved for use in the European Union as a second-line therapy for moderate to severe active rheumatoid arthritis in adults, either alone or in combination with methotrexate. On 31 May 2018 FDA approved Barictinib for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF antagonist therapies.   NCATS

  • SMILES: CCS(=O)(=O)N1CC(CC#N)(C1)N2C=C(C=N2)C3=C4C=CNC4=NC=N3
  • Mol. Mass: 371.417
  • ALogP: 1.1
  • ChEMBL Molecule:
More Chemistry

Drug Pricing (per unit)



United States

$51.8740 - $74.3617
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

baricitinib | incb028050 | incb-028050 | incb-28050 | ly3009104 | ly-3009104


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue